Digestive Enzymes for Indigestion (Functional Dyspepsia)

Verdict: Weak, conflicted evidence for indigestion

Over-the-counter digestive enzymes are not a proven treatment for indigestion (functional dyspepsia). A handful of small trials report symptom relief, but the studies are low quality and major guidelines do not recommend enzymes for this condition.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The evidence rests on just three small, short randomized trials, all reporting benefit but all flawed. A 2023 placebo-controlled trial (PMID 37976892, n=120, 8 weeks) found significant gains in dyspepsia quality-of-life, pain and sleep scores, but it was single-center with undisclosed funding. The most positive trial (DigeZyme, PMID 30156436, n=40) was run by the manufacturer's own founders and employees, a serious conflict of interest, and a 203-patient Chinese trial (PMID 25622633) had no placebo arm, so a true effect cannot be isolated.

No systematic review or meta-analysis supports enzymes for this use, and a 2023 review of functional dyspepsia therapy (PMID 36588474) does not mention them at all. Guideline-backed first-line care is H. pylori test-and-treat, acid suppression, prokinetics and neuromodulators. Mayo Clinic, Cleveland Clinic and Harvard all treat OTC enzymes for indigestion as unproven, noting supplements are largely untested and unregulated for dose and ingredient content.

Regulators like the FDA, NHS and WHO do endorse prescription pancreatic enzyme replacement therapy, but only for diagnosed exocrine pancreatic insufficiency, a separate disease, not ordinary indigestion. Borrowing that legitimacy for OTC products is misleading. The overall picture is a coherent weak (C) grade: a few small, mostly industry-tinged positive trials with no high-quality synthesis or guideline endorsement.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial
PMID: 37976892 2023 RCT (double-blind) n = 120
Finding: Treatment group showed statistically significant improvement in NDI-SF quality-of-life scores, reduced pain severity on Visual Analogue Scale, and improved sleep quality (Pittsburgh Sleep Quality Index) versus placebo, with no reported adverse effects.
🟠 Limited quality Effect size: Significant improvement vs placebo across NDI-SF, VAS pain and PSQI (exact effect sizes not reported in abstract)
View on PubMed
Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study
PMID: 30156436 2018 RCT (double-blind) n = 40
Finding: Multienzyme complex produced statistically significant improvement across all efficacy parameters (P 0.0401 to 0.0033) and a significantly greater between-group effect than placebo (P<0.001); no adverse events.
🟠 Limited quality ⚠️ Industry-funded Effect size: Significant vs placebo on all five symptom scales (P<0.001 between-group)
View on PubMed
Efficacy of compound digestive enzyme tablet for dyspeptic symptoms: a randomized double-blind parallel controlled multicenter clinical trial in China
PMID: 25622633 2014 RCT (double-blind) n = 203
Finding: Two compound digestive enzyme formulations were comparable to each other (80.2% vs 79.4% effective rate, P>0.05) with low adverse-effect rates; no placebo arm, so absolute efficacy over placebo cannot be inferred.
🟠 Limited quality Effect size: Effective rate ~80% in both arms; no placebo comparison
View on PubMed
The treatment of functional dyspepsia: present and future
PMID: 36588474 2023 Cochrane SR
Finding: Comprehensive FD treatment review centered on H. pylori eradication, acid suppression, prokinetics, neuromodulators, fundic accommodation agents and psychological therapy. Digestive enzymes are NOT mentioned as a treatment option — indicating they are not part of the recognized FD therapeutic armamentarium.
Effect size: n/a — review; digestive enzymes absent from recommended therapies
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
CREON is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. source↗
L4b EU EFSA
Neutral
L4c UK NHS
Supportive
PERT replaces the enzymes that your pancreas would normally make. PERT comes as capsules that you take when you eat and helps you digest your food by breaking down carbohydrates, fats and proteins. PERT is available on the NHS with brand names including Creon, Nutrizym and Pancrex. source↗
L4d TW TFDA / 衛福部
Neutral
胰臟酵素製劑「卡利消」全台缺貨,是醫療級胰臟酵素,適用於胰臟外分泌功能不足、慢性胰臟炎、胰臟切除後、先天性胰臟功能障礙等患者……食藥署已啟動專案輸入,尋找國外已上市但台灣未引進的同成分藥品,且已有廠商提出申請。 source↗
L4e WHO
Supportive
Pancreatic enzymes are on the World Health Organization's List of Essential Medicines. Pancreatin is a mixture of several digestive enzymes produced by the exocrine cells of the pancreas, composed of amylase, lipase and protease, used to treat conditions in which pancreatic secretions are deficient, such as surgical pancreatectomy, pancreatitis and cystic fibrosis. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
A huge challenge with dietary supplements is that most haven't been tested as most drugs are, so we don't have definitive information. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-indigestion-INT-digestive-enzymes-001 繁體中文版 →